| Name | Title | Contact Details |
|---|---|---|
Paul Radspinner |
Chief Executive Officer | Profile |
HealthText Inc is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.
Bayside Manor is a Keansburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vial is a leading clinical trial site network that runs highly efficient clinical trials. Vial operates a network of clinical trial research sites within Dermatology clinics across the country. Vials clinical trial recruiting engine, software and oper...
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.